CA
NZ
UK
AU
IND
US
● No identified release, announcement, data readout, or corporate action from the company was behind the advance.
● Apimeds Pharmaceuticals US (APUS) shares rose 41.93% to close at $4.57 on Monday, October 5, 2026.
● No confirmed company-specific news, filing, or clinical update has been identified for the session.
● The stock was swept higher by a broad, regionally concentrated rally in U.S.-listed Brazilian equities.
● No confirmed company-specific release was tied to the session.
● The driver was news tied to partner Sanofi carrying the NuvaxovidVaccineinto the vaccination season.
● Charles River Laboratories led the group, hitting a 52-week high and finishing as the S&P 500's second-best performer.
● Illumina rallied hard, ranking among the S&P 500's stronger performers, as part of a broad life-science tools rally.
● Eli Lilly edged higher with no company-specific news, outperforming most large pharmaceutical peers.
● Merck finished as the Dow's worst performer, with no confirmed company-specific news behind the decline.
Please wait processing your request...